Close
What would you like to look for?
Site search
8 June 2023

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share, for gross proceeds of USD 40.25m, before deducting underwriting discounts and commissions and offering expenses. Ocu-lis intends to use the net proceeds from this offering to advance its development programs in Diabetic Macular Edema and other ophthalmic indications, and for working capital and general corporate purposes. VISCHER AG is representing Oculis Holding AG in this offering for Swiss legal matters with Matthias Staehelin, Balthasar Müller, Timothy Woodtli and Natacha Tang (all Corporate/M&A) as well as Nadia Tarolli Schmidt and Adrian Briner (both Tax).

Authors